Welcome to our dedicated page for Ping An Biomedical Co., Ltd. SEC filings (Ticker: PASW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ping An Biomedical Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ping An Biomedical Co., Ltd.'s regulatory disclosures and financial reporting.
Ping An Biomedical Co., Ltd. reported that it has signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd., which will act as a channel development service provider. The partners share a goal of achieving cumulative sales of RMB 500 million within three years in the health and wellness services market.
Yuan Sheng Mei Yan will use its health management, wellness and government‑enterprise cooperation resources to expand channels and service scenarios, while Ping An Biomedical supplies biotechnology products and technical support. The company describes the cooperation as an important step in commercialization and channel development, aiming to broaden revenue sources and improve market penetration.
Ping An Biomedical Co., Ltd., through wholly owned subsidiary Meridian Industries Limited, entered into a sale and purchase deed with Multi Ridge (Asia) Limited dated July 2, 2026 covering certain trade mark and other IP rights in Hong Kong for USD2,500,000. Completion occurred on July 10, 2026, when legal and beneficial title to the IP rights passed, with an exclusive licence granted to the purchaser’s group pending local registrations.
The deed includes vendor and purchaser warranties and detailed claim mechanics. Claims, including warranty claims, generally require written notice and service of legal proceedings within 24 months after completion. The purchaser bears all stamp duty, filing, registration and similar taxes and indemnifies the vendor. The deed is governed by Hong Kong law with disputes subject to the exclusive jurisdiction of Hong Kong courts.
Ping An Biomedical Co., Ltd. has received an additional 180-day period from Nasdaq to regain compliance with its minimum bid price requirement. The company’s shares have been trading below the required $1 per share, breaching Nasdaq Listing Rule 5550(a)(2).
The new deadline to restore the bid price to at least $1 for 10 consecutive business days is November 23, 2026. Nasdaq granted the extension because the company meets other Capital Market listing standards, and the company indicated it may use a reverse stock split if needed.
The company is evaluating options and intends to regain compliance, but it cautions there is no assurance it will satisfy Nasdaq’s continued listing requirements.
Ping An Biomedical Co., Ltd. CEO Liu Pijun has filed an initial statement of beneficial ownership. The filing shows that 12,250,000 Class A Ordinary Shares are held indirectly through INSPIRETECH LTD, reflecting a substantial position associated with the chief executive but does not report any recent share purchases or sales.
Ping An Biomedical Co., Ltd. filed a Form 3 identifying Liu Xianzhi (XZL) as a director and reporting person. The filing does not list any insider purchase, sale, or other equity transaction, and shows no derivative positions or holding entries in this report.
Ping An Biomedical Co., Ltd. CFO Yang Hongli filed an initial Form 3 as an officer of the company. The filing lists no reportable transactions, and the transaction summary shows zero buys, sells, exercises, gifts, tax withholdings, or restructurings, with derivative positions also not reported.
Ping An Biomedical Co., Ltd. reported that shareholders approved all five resolutions at the 2026 annual general meeting in Hong Kong. The vote authorizes a major overhaul of the company’s share capital structure, including the creation of high-vote Class B shares and a future share consolidation.
Authorised share capital will become US$312,500, divided into 4,900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares, each with a par value of US$0.0000625. Shareholders also adopted a second amended and restated memorandum and articles of association tied to these capital changes.
The meeting further approved a targeted transaction with major shareholder INSPIRETECH LTD, allowing the company to repurchase 12,250,000 Class A shares from INSPIRETECH in exchange for issuing 12,250,000 Class B shares, leaving INSPIRETECH’s total share count unchanged but shifting part of its holding into high-vote stock. A large-scale share consolidation may be implemented within one year at the board’s discretion, with the company’s governing documents to be amended to reflect the consolidation once effected.
Ping An Biomedical has called its Annual General Meeting for March 18, 2026 in Hong Kong. Shareholders will vote on major capital and governance changes.
Key items include amending authorised share capital to US$312,500 divided into 4,900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares, both with a par value of US$0.0000625. The company seeks to adopt a Second Amended and Restated Memorandum and Articles of Association, replacing the existing governing documents.
Shareholders are also asked to authorise a Share Repurchase and Issue in which the board may repurchase 12,250,000 Class A shares from INSPIRETECH LTD, funded by issuing 12,250,000 new Class B shares to INSPIRETECH. Additional proposals cover a share consolidation and related conforming amendments. Holders of ordinary shares at the March 3, 2026 record date may vote in person or by proxy, and the board unanimously recommends voting in favour of all proposals.
Ping An Biomedical Co., Ltd. entered into securities purchase agreements with accredited investors for a private placement of 100,000,000 ordinary shares at $0.04 per share, for total gross proceeds of $4,000,000. The transaction is expected to close within three business days of February 9, 2026, subject to customary conditions.
The shares are being sold in an unregistered offering relying on Section 4(a)(2), Regulation D, and Regulation S exemptions. Investors must be accredited or non‑U.S. persons, and the ordinary shares will carry transfer restrictions and restrictive legends because they are not registered under the U.S. Securities Act.
Ping An Biomedical Co., Ltd. files its annual report on Form 20-F for the year ended September 30, 2025, covering its apparel-focused operations in China conducted through PRC subsidiary New Brand. As of September 30, 2025, 20,500,000 ordinary shares were outstanding.
The company highlights extensive risks tied to operating in mainland China and Hong Kong, including rapid regulatory changes, data and cybersecurity oversight, capital controls, and potential trading prohibitions under the HFCA Act if PCAOB access to auditors is restricted. It notes reliance on PRC and CSRC approvals for overseas listings, and uncertainty around evolving CAC rules.
Business risks include a limited operating history, net losses, going concern and liquidity pressures, heavy dependence on a few major customers, supplier and quality-control risks, rising raw material and labor costs, and seasonality. The report also discloses material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of independent directors and an audit committee.